ENANTA PHARMACEUTICALS INC (ENTA) Stock News

NASDAQ:ENTA - Nasdaq - US29251M1062 - Common Stock - Currency: USD

8.03 +0.63 (+8.51%)

After market: 8.03 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ENTA Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series

2 months ago - By: Yahoo Finance - Mentions: ABBV F TSLA BIP ...

AbbVie Secures FDA Approval to Expand Mavyret’s Label

2 months ago - By: Benzinga - Mentions: ABBV

FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection

2 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

2 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

2 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

2 months ago - By: Yahoo Finance - Mentions: AMAT WMT ADCT ARCT ...

AMAT Earnings: Demand Holding Up So Far

6 months ago - By: Benzinga

The Analyst Verdict: Enanta Pharma In The Eyes Of 4 Experts

2 months ago - By: Zacks Investment Research

Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?

3 months ago - By: Zacks Investment Research - Mentions: PSTV

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: Yahoo Finance - Mentions: TEVA JPM PSTV TTD ...

Why Teva Pharmaceuticals Stock Blasted 6% Higher Today

3 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

3 months ago - By: Zacks Investment Research - Mentions: PROF

Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates

3 months ago - By: Yahoo Finance - Mentions: MTRX BX GS DDOG ...

Matrix Service Company (MTRX): Among the Best Breakout Stocks to Buy According to Analysts

3 months ago - By: Yahoo Finance - Mentions: ZLAB BX GS MTRX ...

Zai Lab Limited (ZLAB): Among the Best Breakout Stocks to Buy According to Analysts

3 months ago - By: Yahoo Finance - Mentions: GOGO BX GS MTRX ...

Gogo Inc. (GOGO): Among the Best Breakout Stocks to Buy According to Analysts

3 months ago - By: Yahoo Finance - Mentions: TARS BX GS CCS ...

Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts

3 months ago - By: Yahoo Finance - Mentions: ORCL BX GS CCS ...

Is Oracle Corporation (ORCL) A Hidden AI Stock to Buy Right Now?

3 months ago - By: Yahoo Finance - Mentions: DHI CMG F

Trading Day: Tariff uncertainty still runs deep

3 months ago - By: Yahoo Finance - Mentions: MARA COMP CC

Why Mara Holdings Stock Plummeted Today

4 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

4 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

5 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

6 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

7 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

7 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

8 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

8 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)